10:32 AM EST, 12/09/2024 (MT Newswires) -- Enanta Pharmaceuticals ( ENTA ) reported Monday positive topline results from a phase 2 study evaluating zelicapavir in children with respiratory syncytial virus.

The company said zelicapavir showed a significant antiviral effect in young children with respiratory syncytial virus and that the experimental drug reduced viral loads in both hospitalized and non-hospitalized infants compared to placebo.

The drug was also well-tolerated and had a favorable safety profile, Enata added.

Shares of the company were down 2.6% in recent trading.

Price: 7.79, Change: -0.21, Percent Change: -2.63